<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Caris Life Sciences, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock</link>
<description>Latest news and press releases for Caris Life Sciences, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/caris-life-sciences-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo695e5429905484111c2fe574.webp</url>
<title>Caris Life Sciences, Inc. Common Stock</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock</link>
</image>
<item>
<title>Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-publishes-study-validating-caris-ai-insights-for-temozolomide-benefit-in-glioblastoma-patients</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-publishes-study-validating-caris-ai-insights-for-temozolomide-benefit-in-glioblastoma-patients</guid>
<pubDate>Wed, 29 Apr 2026 12:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the development and peer-reviewed validation of a new predictive signature to inform therapy selection in glioblastoma (GBM) patients. The study, published in Neuro-Oncology Advances, describes the development and evaluation of the model in a cohort of more than 5,800 GBM patients. The Caris AI Insights in Glioblastoma is featured on the Caris Molecular Tum</description>
</item>
<item>
<title>Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-present-at-the-bofa-securities-2026-health-care-conference-and-the-goldman-sachs-47th-annual-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-present-at-the-bofa-securities-2026-health-care-conference-and-the-goldman-sachs-47th-annual-global-healthcare-conference</guid>
<pubDate>Fri, 24 Apr 2026 12:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.</description>
</item>
<item>
<title>Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Mon, 20 Apr 2026 12:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026.</description>
</item>
<item>
<title>Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-precision-oncology-alliance-welcomes-ucsf-helen-diller-family-comprehensive-cancer-center</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-precision-oncology-alliance-welcomes-ucsf-helen-diller-family-comprehensive-cancer-center</guid>
<pubDate>Fri, 17 Apr 2026 12:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research.</description>
</item>
<item>
<title>Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-right-in-time-clinical-trial-solution-expands-access-to-precision-oncology-trials-for-historically-underserved-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-right-in-time-clinical-trial-solution-expands-access-to-precision-oncology-trials-for-historically-underserved-cancer-patients</guid>
<pubDate>Wed, 15 Apr 2026 12:30:00 GMT</pubDate>
<description>Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide.</description>
</item>
<item>
<title>Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-introduces-multimodal-ai-powered-molecular-insight-to-identify-the-benefit-or-harm-from-the-addition-of-chemotherapy-for-nsclc-patients</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris Life Sciences®</description>
</item>
<item>
<title>Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-38</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-38</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insightIRVING,</description>
</item>
<item>
<title>Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-3</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris</description>
</item>
<item>
<title>Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-advances-precision-oncology-with-new-ai-insights-predicting-brain-metastases-risk-in-breast-and-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-advances-precision-oncology-with-new-ai-insights-predicting-brain-metastases-risk-in-breast-and-lung-cancer</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panelsIRVING, Texas, March 26,</description>
</item>
<item>
<title>Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-present-six-oncology-studies-utilizing-proprietary-multimodal-data-at-the-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-present-six-oncology-studies-utilizing-proprietary-multimodal-data-at-the-aacr-annual-meeting-2026</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision</description>
</item>
<item>
<title>Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-highlights-the-importance-of-dpyd-testing-in-colorectal-cancer-during-colorectal-cancer-awareness-month</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-highlights-the-importance-of-dpyd-testing-in-colorectal-cancer-during-colorectal-cancer-awareness-month</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Caris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patientsIRVING, Texas, March 24, 2026 /PRNewswire/</description>
</item>
<item>
<title>Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-announces-another-breakthrough-study-for-gpsai-in-identifying-and-correcting-misdiagnosis-of-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-announces-another-breakthrough-study-for-gpsai-in-identifying-and-correcting-misdiagnosis-of-cancer-patients</guid>
<pubDate>Fri, 20 Mar 2026 12:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins." This study builds on the body of evidence showing the superiority of Caris' proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types.</description>
</item>
<item>
<title>Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-introduces-powerful-new-caris-ai-insights-to-identify-early-platinum-resistance-in-ovarian-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-introduces-powerful-new-caris-ai-insights-to-identify-early-platinum-resistance-in-ovarian-cancer</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 16, 2026 /PRNewswire/ -- Caris Life Sciences®</description>
</item>
<item>
<title>Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-showcase-five-studies-at-the-2026-uscap-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-showcase-five-studies-at-the-2026-uscap-annual-meeting</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision</description>
</item>
<item>
<title>Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-launches-a-novel-caris-ai-insights-signature-to-guide-first-line-therapy-selection-and-treatment-de-escalation-in-pancreatic-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-launches-a-novel-caris-ai-insights-signature-to-guide-first-line-therapy-selection-and-treatment-de-escalation-in-pancreatic-cancer</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences®</description>
</item>
<item>
<title>Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>/C O R R E C T I O N -- Caris Life Sciences/</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/c-o-r-r-e-c-t-i-o-n-caris-life-sciences</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/c-o-r-r-e-c-t-i-o-n-caris-life-sciences</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>In the news release, Caris Life Sciences Completes Interim Readout of Achieve 1 Study, issued 26-Feb-2026 by Caris Life Sciences over PR Newswire, we are</description>
</item>
<item>
<title>Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-launches-proprietary-ai-insights-signature-which-deepens-understanding-of-response-to-breast-cancer-patients-oral-chemotherapy-drug</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-launches-proprietary-ai-insights-signature-which-deepens-understanding-of-response-to-breast-cancer-patients-oral-chemotherapy-drug</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>IRVING, Texas, Feb. 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision</description>
</item>
<item>
<title>Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts.</description>
</item>
<item>
<title>Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26</title>
<link>https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-report-fourth-133000970</link>
<guid isPermaLink="true">https://6ix.com/company/caris-life-sciences-inc-common-stock/news/caris-life-sciences-report-fourth-133000970</guid>
<pubDate>Mon, 09 Feb 2026 13:30:00 GMT</pubDate>
<description>Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.</description>
</item>
</channel>
</rss>